The therapeutic vaccine: is it feasible?

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Prophylactic human papillomavirus (HPV) vaccines are effective in preventing cervical cancer but do not treat existing infections.
• Limited progress exists in developing immune therapeutic strategies for individuals already infected with high-risk HPV.
• The lack of understanding regarding immune mechanisms controlling HPV-infected or transformed cells hinders therapeutic development.

Purpose of the Study:

• To highlight the challenges and knowledge gaps in developing immune therapeutic strategies for high-risk HPV infections.
• To emphasize the limitations of current preclinical models in predicting human vaccine responses.
• To underscore the potential of HPV-related malignancies as models for cancer immunotherapy.

Main Methods:

• Review of existing literature on HPV vaccines and immunotherapies.
• Analysis of challenges in preclinical modeling for HPV therapeutic development.
• Exploration of HPV-related malignancies as models for cancer immunotherapy.

Main Results:

• Current prophylactic HPV vaccines do not benefit women with existing high-risk HPV infections.
• Preclinical rodent models offer limited insights into human vaccine efficacy and immune correlates.
• HPV-related cancers present a valuable platform for advancing general cancer immunotherapy.

Conclusions:

• Significant gaps in understanding immune mechanisms controlling HPV infections impede therapeutic development.
• There is a critical need for novel immune therapeutic strategies for high-risk HPV.
• Continued research and collaboration hold promise for future HPV therapeutic advancements.